Nubeqa (Darolutamide)

Darolutamide, the active ingredient in Nubeqa, is a androgen receptor inhibitor presented as a tablet for oral use. It treats non‑metastatic castration‑resistant prostate cancer in men who have progressed despite androgen‑deprivation therapy.

GNH USA supplies Nubeqa as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Nubeqa is indicated for prostate cancer that progresses on androgen‑deprivation therapy, specifically targeting the non‑metastatic castration‑resistant disease state. - Non‑metastatic castration‑resistant prostate cancer (MCRPC): Delays the onset of metastasis and improves survival. - High‑risk localized prostate cancer (if considered in clinical practice): May be used as part of combination therapy to reduce recurrence risk. - Metastatic castration‑resistant prostate cancer (mCRS – off‑label): Provides additional androgen‑receptor blockade. - Bi‑annual treatment strategies (off‑label): Used in clinical trials exploring dosing intervals. - Combination regimens (off‑label): Investigated for synergistic effects with other AR target agents. - Patient management of treatment resistance : Helps manage the progress  

Common Side Effects: - Fatigue - Hot‑spot  

Serious or Rare Side Effects: -  

Nucle  t